| Literature DB >> 23627344 |
Charles O Odongo1, Denis A Anywar, Kenneth Luryamamoi, Pancras Odongo.
Abstract
BACKGROUND: Urinary tract infections (UTI) are common in clinical practice and empirical treatment is largely employed due to predictability of pathogens. However, variations in antibiotic sensitivity patterns do occur, and documentation is needed to inform local empirical therapy. The current edition of the Uganda Clinical Guidelines recommends amoxicillin or cotrimoxazole as choice drugs for empirical treatment of community-acquired UTI. From our clinical observations, we suspected that this recommendation was not effective in our setting. In order to examine validity, we sought to identify bacteria from community-acquired infections and determine their susceptibility against these antibiotics plus a range of potentially useful alternatives for treatment of UTI.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23627344 PMCID: PMC3643887 DOI: 10.1186/1471-2334-13-193
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and clinical characteristics of outpatients with urinary tract infection at Gulu regional hospital (n = 82)
| Mean age in years (range) | 46 (37–59) | 23 (18–70) | |
| Pregnancy status among participants | N/A | Not pregnant = 65 Pregnant = 14 | 79 |
| Presenting symptomsa (%) | | | |
| Increased urine frequency | - | 85 | N/A |
| Supra pubic pain/discomfort | - | 77 | N/A |
| Dysuria | - | 68 | N/A |
| Urge incontinence | - | 55 | N/A |
| History of recurrent symptoms (in past 6 months) | 0 | 3 | 3 |
| Immune suppression symptoms | 0 | 0 | 0 |
| Neurological disease affecting micturition | 0 | 0 | 0 |
| Renal angle pain/tenderness | 0 | 0 | 0 |
| Prostatic enlargement | 1 | N/A | |
| Recent catheterization | 0 | 0 | 0 |
| Positive urine sugar | 0 | 0 | 0 |
| Recent antibiotic use (2 weeks)b | 0 | 69 | 69 (20.4) |
| Significant leucocyturia (pyuria)b | 3 | 115 | 118 (34.8) |
| At least 105 CFU/mLc | 3 | 64 | 67 (56.8) |
Key: N/A, Not applicable; CFU, Colony forming units. a calculations only done for female participants as males were too few for meaningful results. b recorded from all patients having any symptom suggestive of a UTI (n = 339).
c test performed only on patients with significant leucocyturia (n = 118).
Susceptibility profile of uropathogens isolated from symptomatic outpatients at Gulu regional hospital, northern Uganda (n = 82)
| Nitrofurantoin (50 μg) | 8 | 14 | 16 | 10 | 5 | 17 | 0 | 1 | 3 | 0 | 0 | 2 | 4 | 0 | 2 |
| Nalidixic acid (30 μg) | 4 | 10 | 24 | 13 | 6 | 13 | 0 | 2 | 2 | 0 | 0 | 2 | 2 | 2 | 2 |
| Cotrimoxazole (25/125 μg) | 5 | 5 | 28 | 5 | 5 | 22 | 0 | 0 | 4 | 0 | 0 | 2 | 2 | 0 | 4 |
| Amoxicillin (10 μg) | 16 | 6 | 16 | 10 | 3 | 19 | 0 | 1 | 3 | 0 | 2 | 0 | 2 | 0 | 4 |
| Amoxi/clav (20/10 μg) | 26 | 3 | 9 | 10 | 10 | 12 | 0 | 4 | 0 | 0 | 2 | 0 | 3 | 1 | 2 |
| Cephalexin (30 μg) | 16 | 13 | 9 | 5 | 8 | 19 | 3 | 1 | 0 | 0 | 0 | 2 | 2 | 0 | 4 |
| Ciprofloxacin (5 μg) | 24 | 0 | 14 | 19 | 5 | 8 | 3 | 1 | 0 | 2 | 0 | 0 | 4 | 0 | 2 |
| Levofloxacin (5 μg) | 29 | 2 | 7 | 13 | 9 | 10 | 2 | 2 | 0 | 2 | 0 | 0 | 3 | 1 | 2 |
| Gentamicin (10 μg) | 24 | 7 | 7 | 26 | 1 | 5 | 4 | 0 | 0 | 2 | 0 | 0 | 6 | 0 | 0 |
| Azithromycin (15 μg) | 6 | 9 | 23 | 10 | 17 | 5 | 4 | 0 | 0 | 1 | 1 | 0 | 5 | 1 | 0 |
| Oxacillin (10 μg)* | 7 | 0 | 2 | - | - | - | - | - | - | - | - | - | - | - | - |
Key: S, Sensitive; I, Intermediate; R, Resistant; * tested on Staphylococcus aureus only (n = 9).
Relative proportions of susceptibility and resistance profiles from all uropathogens isolated from outpatients at Gulu regional hospital, northern Uganda (n = 82)
| Nitrofurantoin (50 μg) | 24 (19.5-40.4) | 20 (15.6-35.1) | 44 (53.7) | 38 (35.3-57.7) |
| Nalidixic acid (30 μg) | 19 (14.7-33.8) | 20 (15.6-35.1) | 39 (47.6) | 43 (41.1-63.6) |
| Cotrim.b (25/125 μg) | 12 (7.8-24.2) | 10 (6.0-21.3) | 22 (26.8) | 60 (56.2-82.4) |
| Amoxicillin (10 μg) | 29 (25.1-46.7) | 11 (6.9-22.7) | 40 (48.8) | 42 (39.9-62.4) |
| Amox-clav c (20/10 μg) | 39 (36.4-58.9) | 20 (15.6-35.1) | 59 (72.0) | 23 (18.7-39.1) |
| Cephalexin (30 μg) | 26 (21.9-42.9) | 22 (17.6-37.8) | 48 (58.5) | 34 (30.7-52.9) |
| Ciprofloxacin (5 μg) | 36 (33.0-55.3) | 6 (2.7-15.2) | 42 (51.2) | 40 (37.6-60.1) |
| Levofloxacin (5 μg) | 44 (42.3-64.7) | 11 (6.9-22.7) | 55 (67.1) | 27 (22.9-44.2) |
| Gentamicin (10 μg) | 62 (57.4-84.4) | 8 (4.3-18.3) | 70 (85.4) | 12 (7.8-24.2) |
| Azithromycin (15 μg) | 26 (21.9-42.9) | 28 (24.0-45.4) | 54 (65.9) | 28 (24.0-45.4) |
Key: a sum of sensitive and intermediate readings, b cotrimoxazole, c amoxicillin-clavulanic acid.
Susceptibility profiles of uropathogens isolated from male patients at Gulu regional hospital, northern Uganda (n = 3)
| S. epidermida | S | S | S | R | R | S | S | S | I | S | |
| S. aureus | R | R | S | I | R | R | R | S | R | S | S |
| E. coli | R | R | I | S | S | S | R | R | S | R | - |
Key: S, Sensitive; I, Intermediate; R, Resistant; TS, Cotrimoxazole; AX, Amoxicillin; AZM, Azithromycin; CL, Cefalexin; NI, Nitrofurantoin; NA, Nalidixic acid; CIP, Ciprofloxacin; LEV, Levofloxacin; CN, Gentamicin; AMC, Amoxicillin-clavulanic acid; OX, Oxacillin, a Staph. epidermidis was associated with prostatic hypertrophy, * tested on Staphylococcus aureus only.